Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 19, ISSUE 3, P570-581, May 1997

Outcomes and costs of positron emission tomography: comparison of intravenous adenosine and intravenous dipyridamole

DOI:https://doi.org/10.1016/S0149-2918(97)80141-5
Outcomes and costs of positron emission tomography: comparison of intravenous adenosine and intravenous dipyridamole
Previous ArticlePharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example
Next ArticleCost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The objective of this study was to compare the cost of intraveneous adenosine and intravenous dipyridamole in positron emission tomography (PET) in patients with coronary artery disease. A retrospective, open-label, case-control, cost-effectiveness analysis was performed in the outpatient nuclear medicine department of a university hospital. Thirty-six patients underwent dipyridamole PET, and 72 matched patients underwent adenosine PET. A cost-effectiveness analysis was conducted using a direct cost accounting approach to estimate institutional costs. Key costs evaluated included acquisition cost, administration cost, monitoring cost, cost of management of side effects, and cost of follow-up care. The total cost of adenosine PET and dipyridamole PET was divided by their respective predictive accuracies to provide a total cost adjusted for efficacy. Adenosine increased heart rate and lowered systolic blood pressure to a significantly greater extent than dipyridamole. The number of patients experiencing adverse drug reactions was significantly greater for adenosine (82%) than for dipyridamole (67%), but the frequency of prolonged (5 minutes) and late-onset side effects was significantly greater for dipyridamole than for adenosine. The frequency of side effects requiring medical intervention was also significantly greater for dipyridamole (53%) than for adenosine (6%). Although adenosine had a significantly greater acquisition cost than dipyridamole, costs of monitoring, management of side effects, and follow-up care were significantly less for adenosine than for dipyridamole. As a result, the total cost of using dipyridamole is significantly greater ($928.00 per patient) than the total cost of using adenosine ($672.00 per patient). Based on these results, adenosine may be the drug of choice for pharmacologic vasodilation for PET.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Rossen JD
        • Simonetti I
        • Marcus ML
        • Winniford MD
        Coronary dilation with standard dose dipyridamole and dipyridamole combined with handgrip.
        Circulation. 1989; 79: 566-572
        • Bolognese L
        • Sarasso G
        • Bonho A
        • et al.
        Dipyridamole echocardiography test: A new tool for detecting jeopardized myocardium after thrombolytic therapy.
        Circulation. 1991; 84: 1100-1106
        • Biagini A
        • Maffei S
        • Baroni M
        • et al.
        Role of dipyridamole echocardiography test on the evaluation of coronary reserve after coronary artery bypass grafting.
        J Thorac Cardiovasc Surg. 1991; 101: 116-120
        • Brown BG
        • Josephon MA
        • Petersen RB
        • et al.
        Intravenous dipyridamole combined with isometric handgrip for near maximal acute increase in coronary flow in patients with coronary artery disease.
        Am J Cardiol. 1981; 48: 1077-1085
        • Casale PN
        • Guiney TE
        • Strauss AW
        • Bourcher CA
        Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging.
        Am J Cardiol. 1988; 62: 799-802
        • Lam JYT
        • Chaitman BR
        • Glaenzer M
        Safety and diagnostic accuracy of dipyridamote-thallium imaging in the elderly.
        J Am Coll Cardiol. 1988; 11: 585-589
        • Wilson RF
        • Wyche K
        • Christensen BV
        • et al.
        Effects of adenosine on human coronary arterial circulation.
        Circulation. 1990; 82: 1595-1606
        • Klabunde RD
        Dipyridamole inhibition of adenosine metabolism in human blood.
        Eur J Pharmacol. 1983; 93: 21-26
        • Gupta NC
        • Esterbrooks DJ
        • Mohiuddin SM
        • et al.
        Adenosine in myocardial perfusion imaging using position emission tomography.
        Am Heart J. 1991; 122: 293-301
      10. Adenoscan® (adenosine).
        Prescription product information. Fujisawa USA, Inc, Deerfield, Illinois1996
      11. I.V. Persantine® (dipyridamole).
        Prescription product information. DuPont Pharma, Billerica, Massachusetts1995
        • National Center for Health Statistics
        Vital Statistics of the United States, 1986.
        Mortality. II. US Public Health Service, Washington, DC1989 (Part A. DHHS Pub. No. (PHS) 89-1101)
        • Belardinelli L
        • Linden J
        • Berne R
        The cardiac effects of adenosine.
        Prog Cardiovasc Dis. 1989; 32: 73-97
        • Moser GH
        • Schroder J
        • Deussen A
        Turnover of adenosine in plasma of human and dog blood.
        Am J Physiol. 1989; 256: C799-C806
        • Iskandrian AS
        • Heo J
        • Askenase A
        • et al.
        Dipyridamole cardiac imaging.
        Am Heart J. 1988; 115: 432-443
        • Picano E
        Dipyridamole-echocardiography test: Historical background and physiologic basis.
        Eur Heart J. 1989; 10: 365-476
        • Hanley FL
        • Grattan MT
        • Stevens MB
        • et al.
        Role of adenosine in coronary autoregulation.
        Am J Physiol. 1986; 250: H558-H566
        • Kurtz A
        Adenosine stimulates guanylate cyclase activity in vascular smooth muscles.
        J Biol Chem. 1987; 262: 6296-6300
      19. aSewster CS Olin BR Hebel SK Drug Facts and Comparisons. Facts and Comparisons, Inc, St. Louis, Mo1991: 85a
      20. bSewster CS Olin BR Hebel SK Drug Facts and Comparisons. Facts and Comparisons, Inc, St. Louis, Mo1991: 750b
        • Ranhosky A
        • Kempthorne-Rawson J
        The safety of intravenous dipyridamole thallium myocardial perfusion imaging.
        Circulation. 1990; 81: 23,384-23,389
        • Cerqueria M
        • Verani MS
        • Schwaiger M
        • et al.
        Safety profile of adenosine stress perfusion imaging in 9,256 patients. Results from the Adenoscan Multicenter Trial Registry.
        J Am Coll Cardiol. 1994; 23: 384-389
        • Taillefer R
        • Amyot R
        • Turpin S
        • et al.
        Comparison between dipyridamole and adenosine in detection of coronary artery disease with T1-201 imaging.
        J Nucl Med. 1996; 3: 204-211

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(97)80141-5

      Copyright

      © 1997 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX